# Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01475461` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01475461](<https://clinicaltrials.gov/study/NCT01475461>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01475461

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 345 participants.

## Technical summary

Registry record NCT01475461. Randomized; triple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2017-01-31.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 345 participants (enrolled count; ClinicalTrials.gov record NCT01475461, source copy `cardio:ctgov-nct01475461-2017-01-31`, retrieved 2026-10-26)
- Start date: 2011-11 (registry gives no type) (ClinicalTrials.gov record NCT01475461, source copy `cardio:ctgov-nct01475461-2017-01-31`, retrieved 2026-10-26)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01475461, source copy `cardio:ctgov-nct01475461-2017-01-31`, retrieved 2026-10-26)
- Completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01475461, source copy `cardio:ctgov-nct01475461-2017-01-31`, retrieved 2026-10-26)
- Results first posted: 2017-01-31 (ClinicalTrials.gov record NCT01475461, source copy `cardio:ctgov-nct01475461-2017-01-31`, retrieved 2026-10-26)
- Countries: United States; Hungary; India; Philippines; Romania; Slovakia; South Africa; Taiwan (ClinicalTrials.gov record NCT01475461, source copy `cardio:ctgov-nct01475461-2017-01-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01475461-2017-01-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Placebo
- Intervention (Drug): PF-04937319 - 3mg
- Intervention (Drug): PF-04937319 - 20mg
- Intervention (Drug): PF-04937319 - 50mg
- Intervention (Drug): PF-04937319 - 100mg
- Intervention (Drug): Sitagliptin - 100mg
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: 9c8f7a6f9c198a429024c24658188ea49f54ca80db9ef70769e54a57744e43bb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
